TD Cowen Maintains Outperform on Boston Scientific, Raises Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joshua Jennings has maintained an Outperform rating on Boston Scientific (NYSE:BSX) and increased the price target from $65 to $77.
March 07, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's Outperform rating is maintained by TD Cowen, with the price target raised from $65 to $77.
The increase in price target by a reputable analyst like Joshua Jennings suggests a strong confidence in Boston Scientific's future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100